

FIGURE 1--Replacement of ERP with small molecule

Primary screen

"peptide displacement assay"



"functional assays"



 $\left(\begin{array}{c} \\ \\ \\ \\ \\ \end{array} \right) \quad \textbf{EPO receptor}$

Biotin-ERP

ERP peptide (compound)

FIGURE 2--Role of small molecule in activation of EPO-R signaling pathway

Study of small molecule effects and potential applications


In vitro studies

- Erythroid system
- Activation of proliferative and anti-apoptotic pathway(s)
- Colony formation in fetal liver cells
- CFU-e/BFU-e formation in bone marrow (mouse and human)
- CNS system
- Activation of anti-apoptotic pathway
- Survival of neural-like cells upon serum withdrawal

In vivo studies

- Effect in animals with carboplatin induced anemia; given I.p. and
- Reticulocytes levels in normal animals


FIGURE 3--Proliferative effect of E5 compound in TF-1 cells



* Same proliferative effect is observed with UT-7 cells * No effect in FDCP1 cells

FIGURE 4--Activation of signaling cascade through EPO-R by small molecule

• Small molecules bind to and activate/phosphorylate EPO-R (UT-7 cells)



IP: α -EPO-R Ab (Upstate technology) WB: α -PY Ab (Upstate technology)

FIGURE 5--Small molecules promote colony formation in the presence of SCF Fetal liver cells (day 3)




FIGURE 6--Effect of EPO-like small molecule on erythroid colony formation in methylcellulose Human bone marrow





FIGURE 7-- Synergy between EM5 small molecule and EPO on erythroid colony formation Human bone marrow



8/17

molecule and EPO on erythroid colony formation FIGURE 8 -- Synergy between E5A24 small Human bone marrow (day 14)





FIGURE 9

EFFECT OF EPO-LIKE HEMATOCRIT IN 8 WEEK OLD C57BL MALE MICE ACTIVITY, SMALL MOLECULE - ON

Dose-response



- Saline Control (N=4)
- Carboplatin Only (N=12)
- Carboplatin + EPO (1.5 ug/kg/day) (N=8)
- Carboplatin + EPO Small Molecule E5 (33 nmole/kg/day) (N=8)
- Carboplatin + EPO Small Molecule E5 (11 nmole/kg/day) (N=8)
- Carboplatin + EPO Small Molecule E5 (3.3 nmole/kg/day) (N=8)

*

CARBOPLATIN (120 mg/kg) ON DAY 0

10

0


FIGURE 10

INDUCED ANEMIA BY **MOLECULE E6 IN 8 ERYTHROPOIETIN** WITH EPO SMALL **WEEK OLD MALE** CARBOPLATIN-**SYNERGISTIC** C57BL MICE **EFFECT ON**

-20

-10

DAY 10




** p<0.01 Versus Carboplatin Alone *** p<0.005 Versus Carboplatin Alon

11/17

FIGURE 11


EFFECT OF E6
ADMINISTERED
BY GAVAGE ON
HEMATOCRIT IN 8
WEEK-OLD MALE
C57BL/J MICE



- ○ SALINE CONTROL
- -E- CARBOPLATIN ONLY
- CARBOPLATIN + E6 GAVAGE (15.7 mg/kg; Days 1-10)



Effect of EPO small molecule on reticulocyte levels in normal animals




EM5 (1100 nmoles/kg; days 1-4)

--- EM5 (110 nmoles/kg; days 1-4)

EM5 (33 nmoles/kg; days 1-4)

SALINE (days 1-4)

FIGURE 13 -- Small molecule activates Bcl-X_L expression



IP: anti Bcl-X_{S/L} WB: anti Bcl- X_L

FIGURE 14--Small molecules activate Bcl-X_L expression

cells	
UT-7	

EM5	E5A24 (µM)	0.3	
	E5A2	0 3	1
		3	1
	(µM)	30	1
	EPO U/ml)	8	
		0.3	
		0	g.
Stimulation:			1

IP: anti Bcl-X_{S/L} WB: anti Bcl- X_L

FIGURE 15 -- Effect of small molecules on P19 cells

P-19 is a neural-like embryonal carcinoma cell line that undergoes apoptosis upon withdrawal of serum

Protocol:

* Treatment with small molecule or EPO 24 hrs prior to serum withdrawal * Serum withdrawal for 48 hours ± EPO or small molecule





FIGURE 16 -- Small molecules prevent neuronal apoptosis after glutamate challenge



* Cortical Neurons isolated from Embryonic day 18 rats

^{*} Treatment with small molecule or EPO for 24 hrs

^{*} Challenge with 300 µM Glutamate for 24 hrs

FIGURE 17 -- Characteristics of EPO-like activity small molecules

- Bind to EPO-R and Activate EPO-R signaling pathway in the presence and absence of hormone
- Bind to different site than hormone and do not interfere with EPO binding
- Act on early erythtroid progenitors
- CFU-e/BFU-e formation in fetal liver cells
- Synergistic effect with EPO in Bone marrow cells (mouse and human)
- Promote EPO like anti-apoptotic activity
- Expression of Bcl-X_L protein
- Increase in neuronal survival during glutamate challenge
- Restore hematocrit level in in vivo animal model, given I.P. and orally
- Act in synergy with EPO
- Increase reticulocyte levels in normal animals